Pfizer's hemophilia B gene therapy succeeds in late-stage study

Summary by Ground News

Pfizer's investigational gene therapy for hemophilia B, fidanacogene elaparvovec, met the primary endpoint in a Phase 3 trial. The trial involved adults males with a moderately severe to severe form of the disease. Pfizer plans to disclose additional key data from the study at a scientific conference in early 2023.

Published 5 months ago

News Articles

More
Filters

All

Left

Center

Right

The Hindu

Pfizer’s haemophilia B gene therapy succeeds in late-stage study

Haemophilia B is an inherited disorder hampers the body's ability to make a blood-clotting protein called factor IX.

5 months ago·India

Read Full Article

Channel News Asia

Pfizer's hemophilia B gene therapy succeeds in late-stage study

US drugmaker Pfizer said on Thursday (Dec 29) its experimental gene therapy for the treatment of hemophilia B, a rare inherited blood disorder, met its main goal in a late-stage study. Data from the study showed that a single dose of the therapy was superior to the current standard of care in helping reduc

5 months ago·Singapore

Read Full Article

Bloomberg

Pfizer Hemophilia Gene Therapy Hits Goal in Final-Stage Study

Pfizer Inc.’s gene therapy for a hemophilia B hit its main goal in a final-stage trial, moving closer to becoming a competitor to a similar one-time treatment that costs $3.5 million.

5 months ago·United States

Read Full Article

Irish Times

Pfizer haemophilia gene therapy hits goal in final-stage study

Results may allow pharma giant to compete with treatment approved in US last month

5 months ago·Dublin, Ireland

Read Full Article

Seeking Alpha

Pfizer says hemophilia B gene therapy met key goal in Phase 3 trial

JHVEPhoto Pfizer (NYSE:PFE) announced Thursday that the company’s investigational gene therapy for hemophilia B, fidanacogene elaparvovec, met the primary endpoint in a Phase 3 trial called BENEGENE-2 involving adults males… This News Pfizer says hemophilia B gene therapy met key goal in Phase 3 trial appeared first on STL.News.

5 months ago·United States

Read Full Article